SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., a clinical-stage pharmaceutical company, has filed a new U.S. patent application for a novel composition aimed at treating metabolic syndrome and aiding in weight loss. This application is part of a collaboration with Clearmind Medicine Inc. and involves a proprietary compound that combines SciSparc’s CannAmide™ with Clearmind’s MEAI compound. The move aligns with the company’s strategy to advance cannabinoid-based pharmaceuticals and taps into the growing obesity treatment market, which is expected to expand significantly in the coming years.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
